Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
[Skip to Navigation] JAMA Oncol. 2022;8(9):1333-1339. doi:10.1001/jamaoncol.2022.1664 Full Text Importance Clinical trial sponsors rely on eligibility criteria to control the characteristics of patients in their studies, promote the safety of participants, and optimize the interpretation of results.
Despite considerable advances in cancer care, rising health care costs have prompted the need for cost-containment strategies.1 This is especially true with regard to new oncology pharmaceuticals—eight of the 10 most expensive drugs on the market are cancer drugs. Since the enactment of the Biologics Price Competition and Innovation Act (BPCIA) in 2010, biosimilars have been developed and marketed as competitive, lower-cost alternatives to newer biologic treatments.
Advances in treatment have completely transformed the way that Americans are living with lung cancer, something that was unthinkable even ten years ago. Since 2015, the U.S. Food and Drug Administration (FDA) has approved 26 new drugs and treatment indications for lung cancer, including 17 biomarker-driven therapies.
As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
